Abstract
Dengue fever is a major public health concern in tropical regions, caused by four distinct serotypes. Sequential infection with a different serotype increases the risks of severe disease through antibody-dependent enhancement (ADE). Huge modeling efforts have focused on primary and heterologous secondary infections, while the dynamics of homologous secondary infections were overlooked due to the assumption of lifelong immunity preventing reinfections by the same serotype.
Recent findings challenge the current understanding of dengue immunity. To explore immunological responses in various dengue infection scenarios, we use a within-host modeling framework that considers individual immunological variations. These models are validated using empirical data. In addition to successfully capturing primary and heterologous secondary infection dynamics facilitated by ADE, this framework provides, for the first time, insights into homotypic reinfection dynamics and discusses its relevance in dengue transmission at the population level, with potential implications for disease prevention and control strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by the Basque Government through the Mathematical Modeling Applied to Health Project, BERC 2022-2025 program and by the Spanish Ministry of Sciences, Innovation and Universities: BCAM Severo Ochoa accreditation CEX2021-001142-S / MICIN / AEI / 10.13039/501100011033.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used here were openly available to the public before the initiation of the study. The data sets analyzed in this study can be obtained from the referenced source [27] of our manuscript. Available from: https://dx.plos.org/10.1371/journal. pcbi.1004951.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data sets analyzed in this study can be obtained from the referenced source [27] of our manuscript. Available from: https://dx.plos.org/10.1371/journal.pcbi.1004951.
